Buy at 20 ; this is a safe solid play

Buy at 25 ; at 25 this is a value play

Buy under 10 ; this could be a big winner in the long term

Buy between 12 to 15 ; this is somewhat safe from healthcare reform - it could even benefit from it - because they are about reducing the cost in health care business

Buy at 15 - this is the price where it was offered on it public offering - could be a better play than MDRX

this is a bio tech company and a play on cancer - this is a speculative stock ; buy under 6/share ; the drug: T-DMI could be a big winner for them - but the success of this company depends on this drug - this drug is the catalyst - will report news on Dec 12 but don't expect them to talk about the drug - this could turn out to become a huge drug company if this drug works out - right now in phase 2

this is another speculative Bio Tech Cancer play - its main drug is FOLOTYN - it was approved and will lauched in Feb - so the big catalyst has already occurred and the stock went up to 8/share - but then the company did a secondary and brought the stock back down - the catalyst now is for FOLOTYN to be approved for use on other cancers - the catalyst is for this drug to become a multiple cancer play